Impact News +++ Ambarella surges after report says company exploring strategic options, including sale (SeekingAlpha) +++ AMBARELLA Aktie +15,53%

ELEDON Aktie

>ELEDON Aktienkurs

2.16 EUR -4.4% (Tradegate)

Ask: 2.46 EUR / 680 Stück

Bid: 2.28 EUR / 730 Stück

Tagesumsatz: 1442 Stück

Realtime Kurs von 8 bis 22 Uhr!

ELEDON Aktie über LYNX handeln

Intraday

1 Jahr

>ELEDON Performance

1 Woche: -11,5%

1 Monat: -22,3%

3 Monate: -35,3%

6 Monate: -49,5%

1 Jahr: -11,5%

laufendes Jahr: -49,5%

>ELEDON Aktie

Name:

ELEDON PHARMACEUT.DL-,001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US28617K1016 / A2QL00

Symbol/ Ticker:

2TK (Frankfurt) / ELDN (NASDAQ)

Kürzel:

FRA:2TK, ETR:2TK, 2TK:GR, NASDAQ:ELDN

Index:

Webseite:

https://eledon.com/

Marktkapitalisierung:

148.17 Mio. EUR

Umsatz:

EBITDA:

Gewinn je Aktie:

-0.026 EUR

Schulden:

0.76 Mio. EUR

Liquide Mittel:

107.64 Mio. EUR

Umsatz-/ Gewinnwachstum:

- / -

KGV/ KGV lG:

5.43 / 5.31

KUV/ KBV/ PEG:

- / 1.5 / -

Gewinnm./ Eigenkapitalr.:

- / -38.15%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

Suchwörter:

ELEDON

Letzte Datenerhebung:

24.06.25

>ELEDON Eigentümer

Aktien: 59.88 Mio. St.

f.h. Aktien: 46.04 Mio. St.

Insider Eigner: 1.4%

Instit. Eigner: 68.2%

Leerverk. Aktien: 2.44%

>ELEDON Peer Group

ACHIEVE LIFE

ACURX

ADVERUM

ANSELL ADR

CHAMPIONS ONCOLOGY

COCRYSTAL

ORASURE

OVID THERAPEUTICS

SENSEONICS

SONIDA

>ELEDON Chart & Kurs - NASDAQ

>ELEDON News

23.05.25 - 21:00	What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock (Zacks)
	Eledon Pharmaceuticals (ELDN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

15.05.25 - 00:09	Eledon Pharmaceuticals GAAP EPS of -$0.08 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.25 - 22:03	Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results (GlobeNewswire EN)
	Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results...

20.03.25 - 21:42	Eledon Pharmaceuticals GAAP EPS of -$0.75 misses by $0.04 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

20.03.25 - 21:03	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results (GlobeNewswire EN)
	Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results...

04.03.25 - 22:09	Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference (GlobeNewswire EN)
	Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference...

07.02.25 - 16:03	Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human (GlobeNewswire EN)
	Eledon Announces Tegoprubart Use as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human...

29.01.25 - 22:09	Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire EN)
	Eledon Pharmaceuticals to Participate in Guggenheim SMID Cap Biotech Conference...

13.01.25 - 13:03	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook (GlobeNewswire EN)
	Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook...

13.11.24 - 10:00	Eledon Pharmaceuticals GAAP EPS of -$0.32 misses by $0.02 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.11.24 - 22:06	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results (GlobeNewswire EN)
	Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results...

29.10.24 - 13:57	Eledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offering (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.10.24 - 12:48	Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire EN)
	Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants...

29.10.24 - 12:48	Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine (GlobeNewswire EN)
	Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation...

11.09.24 - 22:12	Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference (GlobeNewswire EN)
	Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference...

04.09.24 - 13:03	Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients (GlobeNewswire EN)
	Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants...

14.08.24 - 23:24	Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results (GlobeNewswire EN)
	Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results...

29.07.24 - 13:03	Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection (GlobeNewswire EN)
	Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection...

02.07.24 - 22:06	Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire EN)
	Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism...

03.06.24 - 22:03	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation (GlobeNewswire EN)
	Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer das Recht mit Füßen tritt, steht selten fest auf den Beinen. - Stanislaw Jerzy Lec

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram